Description:
This main purpose of this clinical study is to learn about the safety and activity of
margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and
gastroesophageal junction cancer.
Title
- Brief Title: Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Official Title: A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Clinical Trial IDs
- ORG STUDY ID:
CP-MGAH22-05
- NCT ID:
NCT02689284
Conditions
- Gastric Cancer
- Stomach Cancer
- Esophageal Cancer
Interventions
Drug | Synonyms | Arms |
---|
Margetuximab plus pembrolizumab | Keytruda | Margetuximab plus pembrolizumab |
Purpose
This main purpose of this clinical study is to learn about the safety and activity of
margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and
gastroesophageal junction cancer.
Detailed Description
Detailed Description: Both margetuximab and pembrolizumab are monoclonal antibodies used in
combination to treat HER2+ gastric and gastroesophageal junction cancer. This study has two
parts: Dose Escalation and Dose Expansion. The Dose Escalation phase of the study will
evaluate safety of escalating doses of the combination treatment. The Dose Expansion phase
will evaluate safety and activity of the combination in patients with gastric or
gastroesophageal cancer once the final dose and schedule are defined. In addition, a cohort
of patients with HER2+ 3+ gastric cancer patients will be enrolled in the Dose Expansion
Phase.
Trial Arms
Name | Type | Description | Interventions |
---|
Margetuximab plus pembrolizumab | Experimental | margetuximab administered in combination with pembrolizumab | - Margetuximab plus pembrolizumab
|
Eligibility Criteria
Inclusion Criteria:
1. Signed written informed consent.
2. Age ≥ 18 years old (or minimum age based upon local regulations)
3. Unresectable locally advanced or metastatic histologically proven HER2+
gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will
include only gastric cancer patients with 3+ HER2 positivity.
4. HER2+ as 3+ (as defined in AJCC staging manual 8th edition) by IHC or in-situ
hybridation (ISH) amplified.
5. Have received prior treatment with trastuzumab.
6. Have received treatment with at least one or more lines of cytotoxic chemotherapy in
the metastatic setting.
7. Resolution of chemotherapy, immunotherapy or radiation-related toxicities.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
9. Life expectancy ≥ 12 weeks.
10. Measurable disease as per RECIST 1.1 criteria.
Exclusion Criteria:
1. Patients with symptomatic central nervous system (CNS) metastases.
2. Patients with any history of known or suspected autoimmune disease with the specific
exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic
treatment.
3. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
4. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within
the 3 weeks prior to the initiation of study drug.
5. Treatment with radiation therapy within 3 weeks prior to the initiation of study drug
administration.
6. Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other
immune suppressive drugs within the 14 days prior to the initiation of study drug
administration.
7. History of clinically-significant cardiovascular disease.
8. Clinically-significant pulmonary compromise, including a requirement for supplemental
oxygen use to maintain adequate oxygenation.
9. History of (non-infectious) pneumonitis that required steroids or presence of active
pneumonitis
10. Clinically-significant gastrointestinal disorders, such as perforation,
gastrointestinal bleeding, or diverticulitis.
11. Evidence of active viral, bacterial, or systemic fungal infection.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Determine the recommended expansion phase dose of margetuximab in combination with pembrolizumab |
Time Frame: | 9 months |
Safety Issue: | |
Description: | Characterize maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of margetuximab when administered in combination with pembrolizumab |
Secondary Outcome Measures
Measure: | Overall Survival (OS) |
Time Frame: | 24 Months |
Safety Issue: | |
Description: | To investigate the preliminary effect of the combination treatment on OS |
Measure: | Progression Free Survival (PFS) |
Time Frame: | 24 Months |
Safety Issue: | |
Description: | To investigate the preliminary effect of the combination treatment on PFS |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | MacroGenics |
Trial Keywords
- Stomach Cancer
- Gastroesophageal Junction
- Gastric Cancer
- Cancer of the Stomach
- Cancer of Stomach
- Stomach
- Pembrolizumab
- Keytruda
- HER2+
- GEJ
- HER2 positive
- Metastatic
- Margetuximab
- Immunotherapy
- Trastuzumab
- Human epidermal growth factor receptor 2
- Human epidermal growth factor receptor 2-positive
- gastroesophageal junction cancer
- Pembro
- PD-L1
- PD-1
- PD
- Tumor
- Cancer
- KEYNOTE MK3475-PN197
Last Updated
August 19, 2021